The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...